Vertex Pharma (VRTX) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Reports First Quarter 2015 Financial Results
April 29, 2015 4:01 PM EDT-First quarter 2015 total revenues of $139 million, including net product revenues of $130 million for KALYDECO® (ivacaftor) in cystic fibrosis-
-Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2015. Vertex also reiterated its financial guidance for total 2015 KALYDECO revenues and non-GAAP operating expenses. Key financial results include:
      Three Months Ended March 31,    Increase/(Decrease) 2015   2014 $   % (in millions, except per share data)   KALYDECO product revenues, net $ 130.2 $ 99.5 $ 30.7 31 % GAAP net loss $ (198.6 ) $... More